Annovis Bio, Inc.
ANVS- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001477845
No open-market purchases or sales by Annovis Bio, Inc. insiders were filed in the last 90 days; 61 institutions reported holding it in 13F filings for Q2 2026, worth $20.2M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +5 vs. previous quarter
- 61
- 13F valueReported value at the end of Q2 2026
- $20.2M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding ANVS, Q2 2026
No superinvestor reported holding ANVS at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Annovis Bio, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 21, 2026 (view filing) | May 20 | 1 day | Hoffman Michael BDirector | PPurchase | +76.3K | $1.87 | +$142.8K | +2.3%3.36M after | 3 lots |
| Apr 3, 2026 (view filing) | Apr 2 | 1 day | Hoffman Michael BDirector | PPurchase | +713.8K | $2.10 | +$1.50M | +27.7%3.29M after | |
| Dec 8, 2025 (view filing) | Dec 8 | Same day | Hoffman Michael BDirector | PPurchase | +45.0K | $4.31 | +$193.8K | +1.8%2.57M after | 2 lots |
| Nov 25, 2025 (view filing) | Nov 24 | 1 day | Hoffman Michael BDirector | PPurchase | +39.2K | $4.08 | +$159.9K | +1.6%2.53M after | Amended4 lots |
| Nov 21, 2025 (view filing) | Nov 21 | Same day | Hoffman Michael BDirector | PPurchase | +20.0K | $3.50 | +$69.9K | +0.8%2.49M after | 2 lots |
| Nov 18, 2025 (view filing) | Nov 14 | 4 days | Hoffman Michael BDirector | PPurchase | +15.0K | $2.11 | +$31.6K | +0.6%2.47M after | |
| Nov 12, 2025 (view filing) | Oct 28 | 15 daysLate | Maccecchini Maria-LuisaPresident & CEO | PPurchase | +97.6K | $2.05 | +$200.0K | +8.8%1.21M after | |
| Nov 12, 2025 (view filing) | Oct 28 | 15 daysLate | Hoffman Michael BDirector | PPurchase | +975.6K | $2.05 | +$2.00M | +65.9%2.46M after | |
| Oct 13, 2021 (view filing) | Oct 11 | 2 days | Bruck ClaudineDirector | PPurchase | +181 | $27.66 | +$5.01K | +3.1%6.07K after | |
| Oct 13, 2021 (view filing) | Oct 12 | 1 day | White Mark K.Director | PPurchase | +5.00K | $27.40 | +$137.0K | +9.8%56.2K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Annovis Bio, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Empery Asset Management, LP | 2,401,476 | $4.47M | 5.17% | +2,401,476 | New |
| Marshall Wace, LLP | 1,842,339 | $3.43M | 0.00% | +654,840+55.1% | Added |
| Vanguard Capital Management LLC | 1,647,322 | $3.06M | 0.00% | +774,941+88.8% | Added |
| Tudor Investment Corp Et Al | 1,357,134 | $2.52M | 0.01% | +1,357,134 | New |
| Renaissance Technologies LLC | 1,002,200 | $1.86M | 0.00% | +654,600+188.3% | Added |
| Two Sigma Investments, LP | 579,571 | $1.08M | 0.00% | −48,088−7.7% | Reduced |
| Geode Capital Management, LLC | 283,817 | $528.1K | 0.00% | +36,304+14.7% | Added |
| BlackRock, Inc. | 249,856 | $464.7K | 0.00% | +110,323+79.1% | Added |
| Citadel Advisors LLC | 243,682 | $453.2K | 0.00% | +243,682 | New |
| Vanguard Fiduciary Trust Co | 177,530 | $330.2K | 0.00% | +45,488+34.4% | Added |